Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies

International Journal of Cancer

Volumn 123, Issue 4, 2008, Pages 899-904

  Bonovas, Stefanos ^a,b   Filioussi, Kalitsa ^a   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

Chemoprevention; Epidemiology; Metaanalysis; Prostate cancer; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; INCIDENCE; PROSTATE TUMOR;

COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 47049090630     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23550     Document Type: Article

References (59)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
2. Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, Krek W, Cerny T, Gillessen S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8:316-20.
3. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.
4. Homma Y, Kondo Y, Kancko M, Kitamura T, Nyou WT, Yanagisawa M, Yamamoto Y, Kakizoe T. Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. Carcinogenesis 2004;25:1011-4.
5. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002;62:2227-31.
6. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-6.
7. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-9.
8. Greenland S. A critical look at some popular meta-analytic methods. Am J Epidemiol 1994;140:290-6.
9. Emerson JD, Burdick E, Hoaglin DC. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. Contr Clin Trials 1990;11:339-52.
10. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-60.
11. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986;7:177-88.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
14. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
15. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;8:101-29.
16. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group. JAMA 2000;283:2008-12.
19. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-900.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
21. LIPID Study Group (Long-term intervention with pravastatin in ischaemic disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87.
22. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B, Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
23. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J,4 S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7.
24. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. BMC Med 2005;3:6.
25. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group. Long-term follow-up of the west of Scotland coronary prevention study. N Engl J Med 2007;357:1477-86.
26. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-7.
27. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP, Jr, Sternfeld B, Jacobsen SJ, et al. Statin use and risk of prostate cancer in the California men's health study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-25.
28. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-32.
29. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-9.
30. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
31. Sato S, Ajiki W, Kobayashi T, Awata N, PCS Study Group. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 2006;16:201-6.
32. Shannon J, Tewoderos S, Garzotto M, Beer T, Derenick R, Palma A, Farris PE. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
33. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT, Olsen JH. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-7.
34. Singal R, Khurana V, Caldito G, Fort C. Statins and prostate cancer risk: a large case-control study in veterans. J Clin Oncol 2005;23:16S. (suppl; abstr 1004).
35. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
36. Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90:635-7.
37. Blais L, Desgagné A, LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-8.
38. Lovastatin Study Groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079-87.
39. Friedman GD, Flick ED, Udaltsova N, Chan Pharm DJ, Quesenberry CP, Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
40. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7.
41. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
42. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and meta-analysis. Int J Cancer 2007;120:833-43.
43. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
44. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17.
45. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:8606-12.
46. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million subjects. J Clin Oncol 2007;25:3462-8.
47. Bonovas S, Filioussi K, Tsantes A, Sitaras NM. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol 2007;64:255-62.
48. Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, Dellavalle RP. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006;98:1538-46.
49. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, Sorensen HJT. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005;60:534-42.
50. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62.
51. Mamdani MM, Tu K, Austin PC, Alter DA. Influence of socioeconomic status on drug selection for the elderly in Canada. Ann Pharmacother 2002;36:804-8.
52. Ward PR, Noyce PR, St Leger AS. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross-sectional analysis in four primary care trusts in England. J Epidemiol Community 2004;58:89-96.
53. Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002;88:15-9.
54. Brown AF, Gross AG, Gutierrez PR, Jiang L, Shapiro MF, Mangione CM. Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care. J Am Geriatr Soc 2003;51:665-70.
55. Platz EA. Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2175-80.
56. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92.
57. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86.
58. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999;319:312-5.
59. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998;317:1185-90.